News - MedTech & Diagnostics
Changing minds: Should insurers step up in mental health or stick to their lane?

Australia’s mental health system is at a crossroads. Vision 2030 sets out an ambitious promise: universal access to affordable, evidence-based mental healthcare, regardless of income, postcode, or cultural background. But as the sector grapples with crippling workforce shortages and growing demand, that promise risks becoming little more than a slogan.
In a timely conversation with Linda Opie, Head of Health and Wellbeing at HCF, and Sha Nyanu, Psychologist at Ginibi Psychology, the question wasn’t just whether the current system is fit for purpose – it was whether traditional players can deliver on reform alone.
The recent mass resignation of psychiatrists in NSW has only intensified the urgency. With the federal government pledging to roll out a National Early Intervention Service (NEIS) from January 2026, should it be re-elected, the spotlight is now on how private health insurers will fit into the bigger picture.
For HCF, the nation’s largest not-for-profit health insurer, the response has already begun. The insurer is expanding its mental health offerings and building partnerships aimed at increasing access to care.
Still, not everyone is on board. Some clinicians and professional groups remain wary of private health insurers playing a role in care delivery, citing concerns over clinical independence and commercial interests.
As pressure mounts and the existing system continues to struggle, is it still justifiable to cling to rigid boundaries over real-world solutions?
In reimagining healthcare across the entire patient journey, Health Industry HubTM is the only one-stop-hub uniting the diversity of the Pharma, MedTech, Diagnostics & Biotech sectors to inspire meaningful change.
The Health Industry HubTM content is copyright protected. Access is available under individual user licenses. Please click here to subscribe and visit T&Cs here.
News - MedTech & Diagnostics
‘Get comfortable being uncomfortable,’ urges Medtronic VP and Managing Director
The leadership compass is being recalibrated as the old coordinates give way to complexity, contradiction and change. For Liz Carnabuci, […]
MoreNews - MedTech & Diagnostics
Department of Health halts PL changes as industry warns of device viability
The Department of Health has received the final evaluation report into the Prescribed List (PL) reforms from the Nous Group, […]
MoreNews - Biotechnology
argenx inks new agreement with Australian regenerative medicine biotech
Immunology company argenx has entered into a new strategic partnership agreement with Monash University and Monash-originated spinout Myostellar, to develop […]
MoreNews - Pharmaceuticals
The human face rewriting Australia’s most common rare disease, cystic fibrosis
New national data from the Australian Cystic Fibrosis Data Registry (ACFDR) has revealed a significant shift in the trajectory of […]
More